Cargando…

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer

Treatment of triple-negative breast cancer (TNBC) remains an unmet clinical need owing to its lack of an efficient therapeutic target. The targeting of DNA repair by poly(ADP-ribose) polymerase (PARP) inhibitors has shown benefit for patients with the BRCA variation. However, sensitivities to the PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Wen-Jing, Chen, Cheng-Hsun, Chang, Yu-Chu, Cheng, Chia-Hsiung, TsaI, Ying-Huei, Lin, Cheng-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539542/ https://www.ncbi.nlm.nih.gov/pubmed/34683150 http://dx.doi.org/10.3390/jpm11101009

Ejemplares similares

Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer
por: Jian, Dan, et al.
Publicado: (2022)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
por: Jang, Na Young, et al.
Publicado: (2015)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
por: Andreidesz, Kitti, et al.
Publicado: (2021)

PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis
por: Wang, Zhe, et al.
Publicado: (2023)

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
por: Wu, Qin, et al.
Publicado: (2022)

PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer
por: Noureddine, Lara Malik, et al.
Publicado: (2023)

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice
por: Chen, Li-Mei, et al.
Publicado: (2022)

Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer
por: Lai, Yi-Wen, et al.
Publicado: (2021)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
por: Qin, Yi, et al.
Publicado: (2019)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
por: Zimmerli, Dario, et al.
Publicado: (2022)

Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction
por: Chen, Ku-Chung, et al.
Publicado: (2018)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
por: Mazzucchelli, S., et al.
Publicado: (2017)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
por: Dakroub, Rayan, et al.
Publicado: (2023)

Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2015)

The Critical Role of Protein Arginine Methyltransferase prmt8 in Zebrafish Embryonic and Neural Development Is Non-Redundant with Its Paralogue prmt1
por: Lin, Yu-ling, et al.
Publicado: (2013)

Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer
por: Lin, Cheng-Han, et al.
Publicado: (2022)

SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
por: Li, Ming, et al.
Publicado: (2019)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression
por: Liu, Ming, et al.
Publicado: (2020)

Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
por: Jian, Yunting, et al.
Publicado: (2021)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface
por: Cheng, Tzu-Chun, et al.
Publicado: (2015)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Arginine methyltransferase PRMT5 negatively regulates cGAS-mediated antiviral immune response
por: Ma, Dapeng, et al.
Publicado: (2021)

Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism
por: Wang, Shengting, et al.
Publicado: (2023)

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2019)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4uc36fs06qtteua32gusv88k0v